Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 16/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172373 | 0.89 | P2RY14 (0.52) | P2RY14ADRA2AADRA2CHRH1 | |
| SCHEMBL4328492 | 0.89 | P2RY14 (0.52) | P2RY14ADRA2AADRA2CHRH1 | |
| SCHEMBL18172432 | 0.87 | CYP11B1 (0.43) | TP53 | |
| SCHEMBL4329520 | 0.87 | PRCP (0.40) | P2RY14TP53 | |
| SCHEMBL4326401 | 0.85 | TP53 (0.44) | P2RY14ADRA2AADRA2CHRH1TP53 | |
| SCHEMBL18172440 | 0.84 | P2RY14 (0.42) | P2RY14TP53 | |
| SCHEMBL18172401 | 0.82 | PRCP (0.37) | P2RY14TP53 | |
| SCHEMBL18172443 | 0.82 | PRCP (0.39) | P2RY14TP53 | |
| SCHEMBL18172397 | 0.81 | P2RX3 (0.37) | P2RY14TP53 | |
| SCHEMBL18172484 | 0.81 | CNR2 (0.43) | P2RY14TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3286182-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. Hoffmann-La Roche AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577332-B2 | Tetrazole derivatives | MC2R, MC3R, GABRR3 | P2RY14 3175/4885BCL2L1 3280/4885BAD 3214/4885 |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | MC2R, MC3R, GABRR3 | P2RY14 3175/4885BCL2L1 3280/4885BAD 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.